{
    "clinical_study": {
        "@rank": "152858", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Experimental", 
            "description": "SGN-75, everolimus"
        }, 
        "brief_summary": {
            "textblock": "This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of\n      SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell\n      carcinoma."
        }, 
        "brief_title": "A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression\n\n          -  Previously treated with at least 1 tyrosine kinase inhibitor (TKI)\n\n          -  Measurable disease\n\n          -  Eastern Cooperative Oncology Group performance status 0 or 1\n\n          -  Adequate lung and renal function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with anti-CD70-directed therapy\n\n          -  Received more than one prior treatment with an mTOR inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677390", 
            "org_study_id": "SGN75-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "1-2 mg/kg IV every 21 days", 
                "intervention_name": "SGN-75", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "10 mg PO daily", 
                "intervention_name": "everolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Antibody-Drug Conjugate", 
            "monomethylauristatin F", 
            "Carcinoma, Renal Cell", 
            "Antigens, CD70", 
            "Drug Therapy"
        ], 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Cancer Centers - Midtown"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute / Wayne State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "UNC Lineberger Comprehensive Cancer Center / University of North Carolina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }, 
                    "name": "Miriam Hospital, The"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109-1023"
                    }, 
                    "name": "Seattle Cancer Care Alliance / University of Washington"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Seattle Genetics, Inc.", 
            "last_name": "Elaina Gartner, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events and laboratory abnormalities", 
            "safety_issue": "Yes", 
            "time_frame": "Through 1 month post last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Best clinical response according to RECIST Version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Through 1 month post last dose"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or start of new anticancer treatment, an expected average of 6 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Until death or study closure, an expected average of 1 year"
            }, 
            {
                "measure": "Blood concentrations of SGN-75 and metabolites", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1:  pre-dose, 30 minutes, and 2, 4, 8, 24, 168, and 336 hours post dose start;  pre-dose in subsequent cycles, and 1 month post last dose"
            }, 
            {
                "measure": "Incidence of antitherapeutic antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose in most cycles and 1 month post last dose"
            }
        ], 
        "source": "Seattle Genetics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}